| Ticker Details |
Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company. The company operates in one reportable segment: the research, manufacture, and distribution of patient-specific, used in the treatment of specific diseases.
|
| IPO Date: |
November 25, 2014 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.71B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.57 | 2.52%
|
| Avg Daily Range (30 D): |
$0.61 | 1.87%
|
| Avg Daily Range (90 D): |
$0.72 | 2.00%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.45M |
| Avg Daily Volume (30 D): |
.55M |
| Avg Daily Volume (90 D): |
.44M |
| Trade Size |
| Avg Trade Size (Sh.): |
94 |
| Avg Trade Size (Sh.) (30 D): |
58 |
| Avg Trade Size (Sh.) (90 D): |
52 |
| Institutional Trades |
| Total Institutional Trades: |
3,128 |
| Avg Institutional Trade: |
$2.5M |
| Avg Institutional Trade (30 D): |
$2.63M |
| Avg Institutional Trade (90 D): |
$2.56M |
| Avg Institutional Trade Volume: |
.08M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.99M |
| Avg Closing Trade (30 D): |
$3.66M |
| Avg Closing Trade (90 D): |
$3.64M |
| Avg Closing Volume: |
90.4K |
|
|
| Financials |
| |
TTM |
Q4 2025 |
FY 2025 |
|
Basic EPS
|
$.33
|
$.46
|
$.33
|
|
Diluted EPS
|
$.32
|
$.45
|
$.32
|
|
Revenue
|
$276.26M
|
$92.92M
|
$276.26M
|
|
Gross Profit
|
$205.6M
|
$73.13M
|
$205.6M
|
|
Net Income / Loss
|
$16.52M
|
$23.24M
|
$16.52M
|
|
Operating Income / Loss
|
$11.04M
|
$22.42M
|
$11.04M
|
|
Cost of Revenue
|
$70.66M
|
$19.79M
|
$70.66M
|
|
Net Cash Flow
|
$15.04M
|
$-.31M
|
$15.04M
|
|
PE Ratio
|
105.31
|
|
|
| Splits |
|
Oct 16, 2013
|
1:20
|
|
Feb 18, 2010
|
1:8
|
|
|
|
